rbace2
Recombinant proteinexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 31, 2020 (NCT04382950)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Angiotensin-converting enzyme 2INHIBITOR
ACE2 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04375046 | Phase 1 | Aug 31, 2020 | General Organization of Export and Import control system, Kafrelsheikh University |
| NCT04382950 | Phase 1 | May 31, 2020 | General Organization of Export and Import control system, Kafrelsheikh University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| General Organization of Export and Import control system | Government | 2 | 0 | 1 | 2020 |
| Kafrelsheikh University | Academic/Hospital | 2 | 2 | 1 | 2020 |
2 organizations
Page 1 / 1